Sanofi's hemophilia treatment has efficacy, safety confirmed in Phase 3 trial
Sanofi said the study results show the hemophilia A treatment met its primary endpoint with no inhibitor development to factor VIII detected.
Source: mmm-online.com
Karin Knobe News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Karin Knobe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Karin Knobe Today - Breaking & Trending Today
Press Release: ALTUVIIIO late-breaking data at ISTH
ALTUVIIIOTM late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing ...
Source: globenewswire.com
Press Release: ALTUVIIIO late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing
ALTUVIIIOTM late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing XTEND-Kids data confirm the efficacy and safety profile of ALTUVIIIO with simple, weekly 50...
Source: marketscreener.com
Sanofi Finds Way to Maze Therapeutics to Get Its Next Pompe Disease Drug
Sanofi is acquiring rights to a Maze Therapeutics drug candidate for Pompe disease that could give the pharmaceutical giant another option to offer patients who have the rare metabolic disorder. In February, the drug posted positive data from a Phase 1 study.
Source: medcitynews.com
Sanofi - Aventis Groupe: Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children <12 years of age with hemophilia A
Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIO to redefine expectations for treatment of children ophilia A Paris, March 2, 2023. The XTEND-Kids phase
Source: finanznachrichten.de